We got ahold of the presentation that biotech upstart Moderna used to pitch investors in 2017.
The vaccine work has propelled Moderna to command a market value of $55 billion, one of the richest valuations in the biotech industry.For more stories like this, sign up here for Business Insider's daily healthcare newsletter. The US Food and Drug Administration is expected to OK Moderna's vaccine as soon as Friday for emergency use. US officials plan to ship 5.9 million doses to more than 3,000 sites across the country in the following days. Overall, Moderna expects to produce 20 million doses in 2020 and somewhere between 500 million and 1 billion doses in 2021.
The platform's massive potential has wooed investors for years. Moderna CEO Stephane Bancel has said the company will either produce nothing or create dozens of drugs with the technology. That vision has led Moderna to raise massive amounts of capital as a private startup, including $450 million in 2015, $474 million in 2016, and $500 million in 2018.
será de las mejores, eso seguro, el caso que tanto una como otras, se han desarrollado en tiempo súbito, lo cual, es un hito. Lo que con esto estamos en algo nuevo en desarrollo de medicación como nunca antes se ha hecho.
Hmm... I guess none of those investors were from Switzerland. Szczepionka na koronawirusa. Jednak są wątpliwości. Szwajcaria nie zatwierdziła - WP Wiadomości UK Column News - 7th December 2020 | UK Column